Literature DB >> 33339725

A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer.

Xuan-Mei Piao1, Ho Won Kang2, Pildu Jeong1, Young Joon Byun1, Hee Youn Lee3, Kyeong Kim3, Sung Phil Seo2, Won Tae Kim2, Jong-Young Lee4, Yun-Sok Ha5, Yung Hyun Choi6, Sung-Kwon Moon7, Seok Joong Yun8, Wun-Jae Kim9.   

Abstract

BACKGROUND: There is an increasing demand for prognostic immune biomarkers of cancer. The prognostic significance of immune markers has been shown for various cancers, but biomarkers of bladder cancer (BCa) have not been fully evaluated. To clarify the role of human leukocyte antigen DR alpha chain (HLA-DRA) in BCa development, we examined expression of HLA-DRA mRNA in tissue samples of non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC).
MATERIALS AND METHODS: Tissues of 96 NMIBC, 43 MIBC and 59 controls comprising noncancerous BCa surrounding tissues were used to examine the expression of HLA-DRA gene by real-time polymerase chain reaction. The expression of up-stream genes regulating HLA-DRA were also measured to explain the role of HLA-DRA in BCa.
RESULTS: Patients with high grade NMIBC showed higher expression of HLA-DRA than those with low grade NMIBC (P < 0.05). In addition, NMIBC patients who progressed to MIBC showed high expression of HLA-DRA mRNA. Kaplan-Meier analysis showed that NMIBC patients with low expression of HLA-DRA had better progression-free survival than those with high expression (P = 0.004). Moreover, the expression of genes regulating HLA-DRA varied in NMIBC and MIBC, indicating a different immunoregulation effect of HLA-DRA in both cancers.
CONCLUSIONS: High expression of HLA-DRA in NMIBC patients has implications for patient stratification strategies, as well as for BCa tumor immunology.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HLA-DRA; Immune biomarker; Muscle invasive bladder cancer; Nonmuscle invasive bladder cancer; Prognosis

Mesh:

Substances:

Year:  2020        PMID: 33339725     DOI: 10.1016/j.urolonc.2020.11.017

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  7 in total

1.  Identification of immune-related biomarkers associated with tumorigenesis and prognosis in skin cutaneous melanoma.

Authors:  Zhong-Hao Ji; Wen-Zhi Ren; Shuo Yang; Dong-Xu Wang; Zi-Ping Jiang; Chao Lin; Ye Jin; Wen-Tai Tian
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

2.  HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC.

Authors:  Jie Mei; Guanyu Jiang; Yundi Chen; Yongrui Xu; Yuan Wan; Ruo Chen; Feng Liu; Wenjun Mao; Mingfeng Zheng; Junying Xu
Journal:  BMC Cancer       Date:  2022-07-06       Impact factor: 4.638

3.  Identification of Hub Genes and Immune Infiltration in Pediatric Biliary Atresia by Comprehensive Bioinformatics Analysis.

Authors:  Yajing Li; Huichu Ye; Yingxue Ding
Journal:  Children (Basel)       Date:  2022-05-10

4.  Identification of Transcriptional Pattern Related to Immune Cell Infiltration With Gene Co-Expression Network in Papillary Thyroid Cancer.

Authors:  Meiye Li; Jimei Zhang; Zongjing Zhang; Ying Qian; Wei Qu; Zhaoshun Jiang; Baochang Zhao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-04       Impact factor: 5.555

Review 5.  Non-muscle invasive bladder cancer biomarkers beyond morphology.

Authors:  Camilla De Carlo; Marina Valeri; Devin Nicole Corbitt; Miriam Cieri; Piergiuseppe Colombo
Journal:  Front Oncol       Date:  2022-08-03       Impact factor: 5.738

Review 6.  Inclusion Body Myositis and Neoplasia: A Narrative Review.

Authors:  Laura Damian; Cristian Cezar Login; Carolina Solomon; Cristina Belizna; Svetlana Encica; Laura Urian; Ciprian Jurcut; Bogdan Stancu; Romana Vulturar
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

7.  18F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review.

Authors:  Soroush Rais-Bahrami; Jason A Efstathiou; Catriona M Turnbull; Stephen B Camper; Andy Kenwright; David M Schuster; Andrew F Scarsbrook
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-05-19       Impact factor: 5.554

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.